Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorMajem Tarruella, Margarita
dc.contributor.authorGarcía‑Martínez, E.
dc.contributor.authorMartinez, M.
dc.contributor.authorMuñoz Couselo, Eva
dc.contributor.authorRodriguez‑Abreu, D.
dc.contributor.authorAlvarez, R.
dc.date.accessioned2021-09-15T07:39:25Z
dc.date.available2021-09-15T07:39:25Z
dc.date.issued2020-02
dc.identifier.citationMajem M, García-Martínez E, Martinez M, Muñoz-Couselo E, Rodriguez-Abreu D, Alvarez R, et al. SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019). Clin Transl Oncol. 2020 Feb;22:213–222.
dc.identifier.issn1699-3055
dc.identifier.urihttp://hdl.handle.net/11351/6313
dc.descriptionImmunotherapy; Toxicity; irAEs
dc.description.abstractThe use of immune checkpoint inhibitors has emerged as an effective treatment option for patients with several tumor types. By increasing the activity of the immune system, they can induce inflammatory side effects, which are often termed immune-related adverse events. These are pathophysiologically unique toxicities, compared with those from other anticancer therapies. In addition, the spectrum of the target organs is very broad. Immune-inflammatory adverse events can be life threatening. Prompt diagnosis and pharmacological intervention are instrumental to avoid progression to severe manifestations. Consequently, clinicians require new skills to successfully diagnose and manage these events. These SEOM guidelines have been developed with the consensus of ten medical oncologists. Relevant studies published in peer-review journals were used for the guideline elaboration. The Infectious Diseases Society of America grading system was used to assign levels of evidence and grades of recommendation.
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofseriesClinical and Translational Oncology;22
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectImmunoteràpia - Efectes secundaris
dc.subjectCàncer - Tractament
dc.subjectProtocols clínics
dc.subject.meshImmunotherapy
dc.subject.mesh/adverse effects
dc.subject.meshNeoplasms
dc.subject.meshPractice Guidelines as Topic
dc.titleSEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019)
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1007/s12094-019-02273-x
dc.subject.decsinmunoterapia
dc.subject.decs/efectos adversos
dc.subject.decsneoplasias
dc.subject.decsguías de práctica clínica como asunto
dc.relation.publishversionhttps://doi.org/10.1007/s12094-019-02273-x
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Majem M] Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, c/Sant Antoni Maria Claret 167, 08025 Barcelona, Spain. Spanish Group for Cancer Immuno-Biotherapy, GÉTICA, Madrid, Spain. [García-Martínez E] Department of Medical Oncology and Hematology, Hospital Universitario Morales Meseguer, Murcia, Spain. Spanish Group for Cancer Immuno-Biotherapy, GÉTICA, Madrid, Spain. [Martinez M] Department of Medical Oncology, Hospital del Mar, Barcelona, Spain. [Muñoz-Couselo E] Servei de Medicina Oncològica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Melanoma and Other Skin Tumors Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Rodriguez-Abreu D] Department of Medical Oncology, C.H.U. Insular-Materno Infantil de Gran Canaria, Las Palmas, Spain. Spanish Group for Cancer Immuno-Biotherapy, GÉTICA, Madrid, Spain. [Alvarez R] Department of Medical Oncology, Hospital Virgen de la Salud, Toledo, Spain
dc.identifier.pmid31993963
dc.identifier.wos000514525700006
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record